Abstract：
BACKGROUND: There are biological distinctions between gastric cancers from Eastern and Western nations, and therapeutic strategies may differ regionally. Perioperative chemotherapy, adjuvant chemotherapy, and adjuvant chemoradiotherapy (CRT) have all been demonstrated to be effective in the treatment of gastric cancer. The goal of this study was to do a meta-analysis of published studies that were eligible to see if adjuvant chemoradiotherapy was helpful for gastric cancer based on the cancer\'s histology.
METHODS: From inception to May 4, 2022, manual searches were conducted to identify all eligible literature using the PubMed database for the published phase III clinical trial and a randomize-controlled trial testing the role of adjuvant chemoradiotherapy in operable gastric cancer.
RESULTS: Two trials with a total of 1004 patients were selected as a result. Adjuvant CRT was found to have no effect on disease-free survival (DFS) in gastric cancer patients treated with D2 surgery (HR: 0.70 (0.62-1.02), p: 0.07). However, patients with intestinal-type gastric cancers exhibited significantly longer DFS (HR: 0.58 (0.37-0.92), p = 0.02).
CONCLUSIONS: After D2 dissection, adjuvant CRT improved DFS in patients with intestinal-type gastric cancers but not in those with diffuse-type gastric cancers.
METHODS: From inception to May 4, 2022, manual searches were conducted to identify all eligible literature using the PubMed database for the published phase III clinical trial and a randomize-controlled trial testing the role of adjuvant chemoradiotherapy in operable gastric cancer.
RESULTS: Two trials with a total of 1004 patients were selected as a result. Adjuvant CRT was found to have no effect on disease-free survival (DFS) in gastric cancer patients treated with D2 surgery (HR: 0.70 (0.62-1.02), p: 0.07). However, patients with intestinal-type gastric cancers exhibited significantly longer DFS (HR: 0.58 (0.37-0.92), p = 0.02).
CONCLUSIONS: After D2 dissection, adjuvant CRT improved DFS in patients with intestinal-type gastric cancers but not in those with diffuse-type gastric cancers.
摘要：
背景：东西方国家的胃癌之间存在生物学差异，治疗策略可能因地区而异。围手术期化疗,辅助化疗,和辅助放化疗（CRT）均已被证明可有效治疗胃癌。这项研究的目的是对发表的研究进行荟萃分析，这些研究有资格根据癌症的组织学来观察辅助放化疗是否对胃癌有帮助。
方法：从开始到2022年5月4日，使用PubMed数据库进行手动搜索，以识别所有符合条件的文献，用于已发布的III期临床试验和随机对照试验，测试辅助放化疗在可手术胃癌中的作用。
结果：两项试验共选择1004名患者作为结果。发现辅助CRT对D2手术治疗的胃癌患者的无病生存期（DFS）没有影响（HR：0.70（0.62-1.02），p:0.07)。然而,肠型胃癌患者表现出明显更长的DFS（HR：0.58（0.37-0.92），p=0.02)。
结论：D2解剖后，辅助CRT可改善肠型胃癌患者的DFS，但不适用于弥漫型胃癌患者。
方法：从开始到2022年5月4日，使用PubMed数据库进行手动搜索，以识别所有符合条件的文献，用于已发布的III期临床试验和随机对照试验，测试辅助放化疗在可手术胃癌中的作用。
结果：两项试验共选择1004名患者作为结果。发现辅助CRT对D2手术治疗的胃癌患者的无病生存期（DFS）没有影响（HR：0.70（0.62-1.02），p:0.07)。然而,肠型胃癌患者表现出明显更长的DFS（HR：0.58（0.37-0.92），p=0.02)。
结论：D2解剖后，辅助CRT可改善肠型胃癌患者的DFS，但不适用于弥漫型胃癌患者。
